Home › Companies › RCUS

Arcus Biosciences, Inc.

RCUS Lead: Phase 3 4 Biotech Distilled articles ↓

Dermatology Immunology Oncology Protein Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (7 active programs)

casdatifan

Small Molecule Target: HIF-2α, HIF-2a

Clear Cell Renal Cell Carcinoma Phase 3 oral Taiho

quemliclustat

Small Molecule Target: CD73

Pancreatic Cancer Phase 3 Gilead

zimberelimab

Protein Target: PD-1

Clear Cell Renal Cell Carcinoma Phase 1 Gilead
Undisclosed indication WuXi Biologics

domvanalimab

Protein Target: TIGIT

Undisclosed indication Phase 3 Abmuno

AB102

Target: MRGPRX2

Atopic Dermatitis Phase 1 oral
Chronic Spontaneous Urticaria Phase 1 oral

Discontinued (2)

domvanalimab — Non-Small Cell Lung Cancer · futility at interim — domvanalimab-based combination did not improve OS vs pembrolizumab plus chemotherapy
domvanalimab — Gastric Cancer · discontinued due to futility in Phase 3 STAR-221 trial

Biotech Distilled coverage (4)

2026-05-05 UPDATE: Arcus Biosciences (RCUS) - The TKI-Free Bet Gets Its First Receipt 🔒 Paid
2026-04-27 UPDATE: Arcus Biosciences (RCUS) - Gilead Walks Further Away, TIGIT Officially Dies, Stock Rips +25% 🔒 Paid
2026-03-02 UPDATE: Arcus Biosciences (RCUS) - The Catalyst Wrap-Up 🔒 Paid
2026-02-25 Arcus Biosciences (RCUS): Scientific Deep Dive for Casdatifan and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.